Skip to main content Skip to search Skip to main navigation

EMA: Concept Paper on the Revision of EU GMP Annex 11 on Computerised Systems

On 16 November 2022, the European Medicines Agency EMA published a concept paper on the planned revision of Annex 11 "Computerised Systems". The reason: The existing document of the EU GMP Guideline dates back to 2011 and no longer corresponds to the state of the art in various areas or does not consider increasingly important new technologies for the GMP field, according to the EMA.

In short:

A new focus is to be on data integrity, in particular the requirements for "data in motion", and data in archives or in backup, the so called "data at rest". The requirements for providers of e.g., cloud services are also to go into more detail and the meaning of "validation and qualification of the systems" is to be clarified in greater depth. This also applies to the term "commercial off-the-shelf products". References to ICH Q9 and thus to quality risk management will also be added.

In addition to these classic topics, developments in the field of artificial intelligence will be included in the future. There are currently no regulatory guidelines or expectations for AI (artificial intelligence) or ML (machine learning). The main focus here should be on the relevance, appropriateness and integrity of the data with which these models are tested and, on the results (metrics) of such tests.

Of interest is a reference (33.) to the FDA's draft document "Computer Software Assurance for Production and Quality System Software", which was recently published. This important US document is to be reviewed for possible regulatory relevance to Annex 11.

The timeline for a new Annex 11:
The consultation period ends on 16 January 2023, with a draft document to be released for consultation in December 2024. Finalisation of the document is planned for 2026.


Source:

EMA: Concept paper on EU Annex 11 on Computerised Systems

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

FDA: New Draft Guidance on Impurity Specifications for Antibiotics

The US FDA has issued a new draft guidance (April 2026) on Impurity Specifications for Antibiotics.
Read more
EDQM: Guidance on Traceability of Medicines in Hospitals

EDQM: Guidance on Traceability of Medicines in Hospitals

The EDQM has published new guidance on the traceability of medicines in hospital settings. The aim is to improve traceability up to the point of administration and strengthen patient safety.
Read more
Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Which Measures are Crucial for Implementation and Monitoring of Data Integrity?

Here's the answer:
Read more
Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

Contamination Control Strategy (CCS) – Not Just an Extended Site Master File

At the GMP-PharmaCongress in Wiesbaden, GMP inspector Frank Sielaff (Regional Authority in Darmstadt, Germany) shared practical insights from recent inspections, high-lighting deficiencies in CCS implementation.

Read more
EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

EMA/HMA: Call for Regulatory Updates for Radiopharmaceuticals

In their „Horizon Scanning Report“, EMA and HMA have recommended updates to the regulatory framework to keep pace with developments in radiopharmaceuticals. Due to their unique characteristics these products require specific regulatory and scientific approaches.
Read more
How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

How can the Specific Requirements for Sterile Products be Taken into Account in the Quality Management System?

Here's the answer:
Read more
Previous
Next